Just a few months ago, the novel coronavirus disease 2019 (COVID-19) hit the United States and rapidly changed lives. As reopening efforts and recovery plans start to take hold, it should be recognized that community pharmacies are ideally positioned to support this national effort.

As social distancing remains encouraged, pharmacies have stepped up to adapt their services in many ways. This includes ensuring that the strain of the global pandemic does not interfere with the care of patients with chronic and complex conditions. Our 

dives into the important role of the pharmacist in helping patients with HIV manage their disease states, especially during a time when in-person counseling is not always plausible and telemedicine takes center stage.

States are slowly easing barriers to pharmacist-provided COVID- 19 testing. In this issue, you’ll find an 

 on the current state of coronavirus testing in the pharmacy, including the maze of federal, state, and supply chain practicalities. As Christopher Daly, PharmD, MBA, BCACP, said, “Pharmacy is going to be a big part of the testing capabilities, especially when the second wave hits. But you can’t just start testing tomorrow.”

In our May issue, we provided an update on the vaccine de- velopment pipeline. In this issue, Jennifer Gershman, PharmD, 

advises how pharmacists can combat the antivaccination movement and promote other recommended vaccines

 by using logic and data to reassure patients. These tips will also surely help pharmacists when an impending COVID-19 vaccine becomes available in the future.

Additionally, in our technology section, we discuss 

how pharmacies can protect themselves from cyberattacks and avoid HIPAA violations

. Investing in the right tools and training for your business’ technology systems is crucial to preventing a potential data breach. 

Education remains key, whether you’re staying up-to-date on the latest products or brushing up on counseling points for your patients. 

® remains committed to providing phar- macists with the most up-to-date industry information. Continue to follow us on drugtopics.com and stay tuned for a new, updated look coming soon.

Articles

As reopening efforts and recovery plans start to take hold, it should be recognized that community pharmacies are ideally positioned to support this national effort.

Adapt to a “New Normal” During Uncertain Times

On February 27, 2020, the FDA approved an intravenous solution of amisulpride (Barhemsys; Acacia Pharma) to treat and prevent postoperative nausea and vomiting (PONV). For prevention, amisulpride can be used alone or with another antiemetic. For PONV treatment, it may be administered to patients who received no prophylactic therapy or received a different drug during prophylaxis. Amisulpride, a selective D2/D3 dopamine receptor antagonist, is the first of Acacia Pharma’s pipeline medications to be approved after showing positive results in 4 phase 3 clinical trials.

Data from 4 randomized double-blind, placebo-controlled, multicenter trials supported the approval of amisulpride for prevention and treatment of PONV.

Two studies evaluated the agent’s use for prevention of PONV in patients undergoing general anesthesia and elective surgery. In both studies, treatment groups were matched for PONV risk factors. In study 1, participants (n = 342) received 5 mg of amisulpride (n = 176) or placebo (n = 166). In study 2, participants (n = 1147) received amisulpride plus standard therapy of ondansetron, betamethasone, or dexamethasone (n = 572) or placebo plus a standard antiemetic (n = 575). The primary outcome in both studies was complete response (CR), defined as no emesis and no use of rescue medication in the 24-hour postoperative period. In both studies, groups receiving amisulpride demonstrated increased rates of CR: study 1, 44% in the amisulpride treatment group vs 33% in the placebo group (difference, 12%; 95% CI, 2%-22%); study 2, 58% in the amisulpride plus standard antiemetic group vs 47% in the placebo plus standard antiemetic group (difference, 11%; 95% CI, 5%-17%).

Amisulpride’s effectiveness for treating PONV was demonstrated in 2 studies using the agent as a 10-mg single dose. In study 3
(n = 369), participants did not receive prior prophylaxis. Participants in study 4 (n = 465) received prior prophylaxis therapy with a nondopaminergic antiemetic (77%, 5-HT3 receptor antagonist; 65%, dexamethasone; 10%, other medication). Both studies evaluated the CR rates within 24 hours after administration with amisulpride excluding emesis within the first 30 minutes. Groups receiving amisulpride demonstrated increased rates of CR: study 3, 31% in the amisulpride treatment group vs 22% in the placebo group (difference, 10%; 95% CI, 1%-19%); study 4, 42% in the amisulpride treatment group vs 29% in the placebo group (difference, 13%; 95% CI, 5%-22%).

Overall, participants given amisulpride experienced significantly lower incidence of emesis, nausea, and rescue medication use compared with placebo, as monotherapy, and combined with other antiemetics.

Among all the studies of amisulpride, the adverse event (AE) profile was similar to that of the placebo groups. The most common AEs include infusion-site pain (6%), increased serum prolactin (5%), hypokalemia (4%), chills (4%), procedural hypotension (3%), and abdominal distention (2%). QT prolongation is a dose- and concentration-dependent AE associated with amisulpride use. It is unlikely to contribute to a meaningful QT prolongation at approved doses, but monitoring is recommended in patients who are at higher risk; have preexisting arrhythmia or cardiac conduction disorders, congestive heart failure, hypokalemia, hypomagnesemia; or receive concurrent medications that can prolong the QT interval (such as ondansetron). Amisulpride is extensively renally eliminated; its use should be avoided in patients who have severe renal dysfunction, with an estimated glomerular filtration rate less than 30 mL/min/1.73m2, because these patients may be at increased risk of AEs.

For prevention of PONV, amisulpride is given as a 5-mg, single-dose infusion over 1 to 2 minutes at the induction of anesthesia. This may be administered as monotherapy

or with another antiemetic medication. For treatment of PONV, amisulpride is infused as a 10-mg dose over 1 to 2 minutes in the event of nausea or vomiting after surgery.

Barhemsys. Acacia Pharma; 2020. Accessed May 19, 2020. https://www.accessdata.fda.gov/drugsatfda_docs/ label/2020/209510s000lbl.pdf

On February 27, 2020, the FDA approved an intravenous solution of amisulpride (Barhemsys; Acacia Pharma) to treat and prevent postoperative nausea and vomiting. 

Barhemsys (Amisulpride) for Postoperative Nausea and Vomiting

In early April, the US Department of Health & Human Services authorized licensed pharmacists to order and use coronavirus disease 2019 (COVID-19) tests approved by the FDA. By mid-May, about two-thirds of states had adjusted regulations for pharmacist-provided testing, but just a handful of pharmacies had managed to navigate the maze of federal, state, and supply chain practicalities.

In California, pharmacy, medical, and consumer groups lobbied Gov Gavin Newsom and regulators for nearly 6 weeks before the state’s Department of Consumer Affairs eased restrictions that prevented most pharmacies from testing.

“This waiver will allow pharmacists to order COVID-19 tests for their patients and collect specimens to send to a laboratory for processing,” said Richard Dang, PharmD, APh, BCACP, COVID-19 Task Force chair and speaker for the California Pharmacists Association. “I am not currently aware of a pharmacy testing site that is set up, but I am hopeful that will change.”

Andrew Cuomo, governor of New York, issued his own executive order clearing the way for pharmacists to order and administer COVID-19 tests in late April.

“We got the privilege of testing from the governor, and we’re finding out that pharmacies need a laboratory certificate from the state before we can offer testing,” said Christopher Daly, PharmD, MBA, BCACP, a board member of the Pharmacists Society of the State of New York. “Beyond that, there are questions about [personal protective equipment], where will we procure the tests, billing, and more. Pharmacy is going to be a big part of the testing capabilities, especially when the second wave hits. But you can’t just start testing tomorrow.”

A key problem involves meeting both state scope of practice and state laboratory requirements. At deadline, the FDA had issued emergency use authorizations for 4 point-of-care COVID-19 tests. The tests require a Clinical Laboratory Improvement Amendments (CLIA) certificate of waiver, typically issued by the state health department.

The first step to pharmacy-based COVID-19 testing is the certificate of waiver, said Allie Jo Shipman, PharmD, MBA, director of state policy for the National Alliance of State Pharmacy Associations. Next comes navigating the scope of practice regulations, which can be a frustrating exercise.

A recent poll by National Community Pharmacists Association (NCPA) found that most of its members want to test for COVID-19. “As an association, we have had to temper expectations a bit,” said Hannah Fish, PharmD, CPHA, NCPA’s associate director of strategic initiatives. “Testing is coming, but getting there is a step-by-step process, and you need to work out the logistics.”

Reimbursement remains uncertain. Federal regulators require insurers to cover COVID-19 testing at no cost to patients, but there are no requirements to reimburse test providers. Commercial insurers have mechanisms to cover medical costs but not pharmacy costs.

“Centers for Medicare & Medicaid Services is trying to take advantage of access to pharmacies as providers, but they are hemmed in by existing statutes,” said Tom Kraus, JD, vice president of government relations for the American Society of Health-System Pharmacists. “They are creating work-arounds like having pharmacies register as labs to get paid, and there are mechanisms like incident-to payments for pharmacists in health systems or in medical practices. But there are no mechanisms that work for most community pharmacies. That’s something we need legislation to fix.”

“Testing is coming, but getting there is a step-by-step process, and you need to work out the logistics.”

States Slowly Ease Barriers to Pharmacist-Provided COVID-19 Testing

harmacists, pharmacy technicians, and other pharmacy staff felt overtaxed even before the coronavirus disease 2019 (COVID-19) pandemic hit, according to findings from the 2019 National Pharmacist Workforce Study. The survey results showed that 69% of full-time pharmacists reported that their workload “increased” or “greatly increased” compared with the prior year.

Although the profession is much more racially and gender diverse than in previous years, pharmacy staff reported age, race, and gender discrimination, according to the findings. The Midwest Pharmacy Workforce Research Consortium has conducted the annual study for the Pharmacy Workforce Center (PWC) since 2000.

Among full-time, actively practicing pharmacists, 71% rated their workload level at their primary place of employment as “high” or “excessively high” in 2019, compared with 66% and 68% of full-time pharmacists in 2014 and 2009, respectively.

The highest proportions of full-time pharmacists rating their workload as “excessively high” or “high” or were in chain (91%) and mass merchandiser (88%) settings; the lowest proportions were in independent community (48%) and ambulatory care (57%) pharmacy settings, the PWC said.

“Employers, such as large pharmacy chains and others, should consider how they can boost fulfillment and lower exhaustion amongst their employees, which will lead to retaining a strong workforce. Perhaps there are lessons to be learned from independent and hospital settings [that] are succeeding at meeting the needs of its personnel,” PWC said in a statement.

Overall, 44.2% of full-time pharmacists received an increase in base pay in 2019 compared with 31.7% in 2014; 48.4% said their base pay stayed the same.

Full-time pharmacists in community retail pharmacies (approximately 12%) reported a base pay decrease in the past year compared with full-time pharmacists in hospital settings (2%).

Nearly a third (31%) of pharmacists reported experiencing incidents of discrimination in 2019. “The most common type of harassment reported by pharmacists was hearing demeaning comments related to race/ethnicity at 15.7%,”PWC said in a statement.

Just 15.9% of all discrimination incidents and 17.2% of all harassment incidents were reported to an employer.

In good news, the profession is starting to become more diverse. Women made up nearly two-thirds of the pharmacy workforce in 2019 compared with 46.4% in 2009. More women are also taking on leadership roles, accounting for nearly 60% (58.8%) of pharmacists in management positions in 2019.

The percentage of nonwhite licensed pharmacists also surged 46% in the past 5 years, reaching 21.8% in 2019. The percentage of black pharmacists more than doubled to 4.9%. 

The profession continues to trend younger, PWC found. In 2019, 48.8% of practicing pharmacists were 40 years or younger, compared with just 24.4% in 2009. “This has positive implications for patients, as these practitioners are trained in new systems of care and will play key roles in the future of pharmacy practice,” PWC said.

Survey results reveal improvements and challenges in the workplace.

Pharmacists Feel Overworked, Face More Discrimination

Professional burnout among pharmacists, already a growing concern in the United States, could be exacerbated by the coronavirus disease 2019 (COVID-19) crisis. The current pandemic strains pharmacy capacity and exposes persistent underlying problems, according to 3 experts on pharmacy burnout.

A national survey of more than 4700 pharmacist concluded that, although more than half (54.2%) of respondents reported meaningful work, 32% and 33% also said they felt “a lot” or “totally” emotionally and physically exhausted. Community pharmacists demonstrated higher rates of work exhaustion and interpersonal disengagement, as well as lower levels of professional fulfill- ment, compared with those practicing in hospitals and other work settings. A poster showing the results was pre- sented in the 2020 American Pharma- cists Association (APhA) Virtual Poster Hall Gallery.

In a video interview with Drug Topics®, study coauthor Matthew Witry, PharmD, PhD, noted the 3 predominant factors of burnout:

Along with already slumping pharmacist retention rates and closing pharmacies, the pandemic puts immense pressure on the health care profession, as pharmacists work tirelessly to support their patients and communities.

The survey findings also suggest that larger pharmacy chains should emulate independent pharmacy workplaces to improve fulfillment and lower levels of exhaustion.

“We saw lower scores for a sense of control at work in those corporate settings, which isn’t surprising, since there is more of a corporate structure with a lot of those retail environments, where a lot of those decisions are getting made at higher levels of management,” said Witry, an assistant professor in the Department of Pharmacy Practice and Science/Division of Health Services Research at The University of Iowa College of Pharmacy in Iowa City.

Findings from a separate survey conducted by the National Pharmacy Technician Association showed that most chain and mass retail pharmacy technicians do not feel safe at work during the current pandemic, with just 26.1% reporting feeling safe compared with 63.8% of independent pharmacy technicians.

Caroline Gaither, PhD, FAPhA, coauthor of the study presented at APhA, senior associate dean of the Professional Education Divisions, and a professor in the Department of Pharmaceutical Care and Health Systems at the University of Minnesota College of Pharmacy, agreed that chain pharmacies may be experiencing more acute levels of burnout amid the pandemic.

“The corporate-owned chain environment in particular is really suffering related to their satisfaction. The workload has increased very much, and we’ve been looking at that, as well,” she told Drug Topics®. “They’re telling us that the workloads have gotten higher and the staffing has decreased, and that has increased their feeling of job stress and also influenced their satisfaction levels.”

The survey results linked burnout in all domains with the likelihood of leaving one’s position, suggesting that reducing burnout could help promote pharmacist retention, according to the authors.

As the pandemic intensifies burnout factors, pharmacy closures in both rural and metropolitan areas in recent years, as well as discussions of pharmacy benefit managers cutting reimbursements, compound the issue.

“If anything, this pandemic has made us think about the importance of access. Having pharmacies where we need them is important,” Witry said.

Jon Schommer, MS, PhD, RPh, also a study coauthor and a professor in the Department of Pharmaceutical Care and Health Systems at the University of Minnesota College of Pharmacy, encouraged scrutinizing workplace conditions during the pandemic.

“In addition to burnout, which is something that you would like to avoid, we also do research in the area of what’s called well-being,” he told Drug Topics® in a video interview. “And that’s being able to have constructive conditions at work and beyond, even in your personal life, that enable workers to thrive and achieve their full potential.

“Part of that also is something called resilience: the ability of a person or a group of people or even a system to adapt and rebound and even grow from adverse conditions, stress, or trauma,” he continued. “When you think of this COVID-19 situation, we’re all also keeping an eye on work conditions that will support resilience. Can you actually grow and take advantage of very stress- ful and difficult situations?”

Gaither discussed the National Academies of Science, Engineering, and Medicine’s explanation of clinician burnout, which includes 2-pronged influences. On 1 side are the frontline workers and health care providers working for a particular health care organization that has varying policies and procedures, whereas the other side determines work system factors, including job demand, workload, and the number of work hours.

“If there’s a good balance there, then the health providers are able to really thrive and do the work, but when the job demands become too high, that’s where you can get into some of the more negative consequences,” Gaither said.

“Now, the other piece of that is, they say that these work system factors are also influenced by the individual-so, how much resilience that person has, their ability to cope with adversity, and also how much their work interferes with their personal life,” Gaither continued. “I really like the model, because they’ve started to talk about the system factors that are beyond what the individual provider is able to contribute and that the burnout is not necessarily related to some kind of individual failure, but it’s really related to kind of the way the work environment is structured.”

A contributing factor to burnout, according to Schommer: Community pharmacy practice is increasingly pressuring pharmacists to conveniently and quickly distribute medications.

“We’re finding that in community pharmacy practice, the distribution of pharmaceuticals is so vital, and you have to have that pressure on you all day long to be as efficient as possible. At the same time, community pharmacies are being recognized by the public by government agencies, such as CDC [the Centers for Disease Control and Pre- vention]...as health care access points, that you can get vaccinations, immunizations, screenings, and point of care testing,” he said. “There are a lot of patient care and public health services that are being provided.”

The experts put forth the idea of moral injury, in which health providers pursue their responsibilities but face constraints within their organization that affect their well-being and ability practice at their best.

Pharmacists remain eager to take on more responsibilities, according to Witry. “Pharmacists are probably feeling really appreciated. They’re making a difference-getting that care to people, being that access point, answering important questions, being a source of care,” he said. “When people aren’t going to their primary care physician appointments, they can still call their pharmacist or they can still talk to the pharmacist across the plexiglass.”

However, issues within the health care systems must be addressed so that pharmacists can do their job and avoid burnout.

“Do the pharmacists feel that their employers kind of have their backs? Do they feel supported? Are employers really stepping up to take care of their health providers? I think [that] is something that also probably needs to change,” Gaither said. “And then this idea of the profit motive in health care- there’s a lot of things that we could do better with if we had more resources and more reimbursements...to really provide patient care.”

“Are employers really stepping up to take care of their health providers? I think [that] is something that also probably needs to change.”

Experts Examine the Many Factors of Pharmacist Burnout

The uptick in dietary supplement use and integrative health and medicine practices in the United States creates both opportunities and concerns for pharmacists and health providers, who need to stay well informed to help patients avoid harmful effects. Some patients may seek vitamin or herbal supplements for health and wellness, often believing that these are safer than conventional OTC and prescription pharmaceutical products. However, so-called natural remedies come with their own set of health risks.

“Dietary supplements are very helpful and really needed when they are chosen correctly and properly,” said Farzana Kennedy, RPh, FACA, owner and president of Dalitso, an integrative pharmacy in Alexandria, Virginia. “Often, they can be harmful if not properly monitored or checked for interactions or contraindications in a patient who has preexisting conditions.”

Dietary supplement use has reached an all-time high, with 77% of Americans reportedly using these products, according to a 2019 survey conducted by the Council for Responsible Nutrition. The increased patient demand for non-pharmacologic health options has created unprecedented opportunities for pharmacists to expand their interactions with patients.

Many patients consider community pharmacies the ideal place to purchase vitamins and other dietary health supplements. Pharmacists can positively affect the patient experience by:

Providing supplement education Making supplement recommendations

Assessing for interactions, contraindications, and toxicities Collecting a patient’s complete medication history, including supplements

Assessing for drug-drug, drug- micronutrient, and drug- supplement interactions

Helping patients evaluate natural products for quality-related issues

Pharmacists can also educate patients about the potential effects of taking dietary supplements on laboratory test validity and results.

“In general, validating and interpreting laboratory test results can be key tools in helping health care professionals optimize clinical decisions related to their patients’ health,” said Cathy Rosenbaum, PharmD, RPh, MBA, CHC, CDP, a holistic clinical pharmacist and founder and CEO of Rx Integrative Solutions in Blue Ash, Ohio. “Pharmacists are uniquely poised to prospectively educate the public on any laboratory test interferences with medications, supplements, or micronutrients to minimize safety risks.”

Biotin: A Lesson in Disclosing Supplement Use

Through their frequent interaction, patients and pharmacists often build a strong rapport and a trusting relationship in which patients feel comfortable discussing supplements. Pharmacists should advise their patients to also report all dietary supplement and natural product use to physicians prior to any blood testing, Rosenbaum said.

A laboratory-testing interaction involving biotin illustrates several important ways pharmacists can help keep patients safe through counseling. Many patients who pick up a bottle of biotin, a water-soluble B vitamin, view it as a harmless supplement to enhance physical appearance (eg, skin, hair, nails). Rosenbaum warns that this assumption can be problematic because of the lack of clinical research with standardized biotin dosing to support these claims. The scientific community has long known that biotin functions in the body as a cofactor for enzymes involved in carboxylation reactions, and it plays a role in fatty acid and carbohydrate oxidation. Daily amounts of biotin needed for general health is defined in different ways because there is no standardized recommended dietary allowance or nutrient intake for this nutrient. A generally suggested intake for adults is between 30 mcg and 100 mcg a day.

OTC biotin products come in many doses that are significantly higher than the amount provided in adequate nutrition, some as much as 10,000 mcg per dose for therapeutic indications.

Several reports link high-dose biotin supplementation to falsely elevated levels of the thyroid hormones triiodothyronine and levorotatory thyroxine and falsely low thyroid-stimulating hormone levels, all used to diagnose and monitor thyroid disease. Taking supplemental biotin at 20 mg or more on a daily basis may interfere with thyroid bioassays that use streptavidin–or avidin–biotin systems.

Excessive biotin intake can lead to misdiagnosis, inappropriate treatment, or even death. For example, biotin supplementation can produce altered levels of troponin, one of the biomarkers elevated during acute myocardial infarctions. According to a November 28, 2017, FDA statement on biotin concerns, a patient who took high doses of biotin died because of complications related to falsely low troponin levels found in a test that relied on biotin technology. Because patients may be unaware of biotin interference, they may not report taking biotin supplements, and may even be unaware they are taking the supplement at all, according to the FDA.

CBD and Medical Cannabis: Countering Ads that Overpromise

The challenges of providing patient guidance in integrative medicine are not exclusive to biotin. The recent explosion of cannabis and cannabidiol (CBD) products presents more issues because these products are routinely promoted as completely safe, with no risks. Buying into this hype could have deleterious consequences for patients.

“Pharmacists providing direct patient care by providing medical cannabis or hemp-based CBD products must know and understand patient diagnoses, treatment plans, and how to monitor patients for interactions,” Kennedy told Drug Topics®.

“One big problem is that cannabis dosing is not standardized, and therefore, pharmacists should educate themselves to help patients receive optimal care regarding the product and dose that will sit well with them without [adverse] effects or other undesired feelings.”

Kennedy also stated that the ubiquitous deluge of CBD products from companies draws increasing concern about quality. She urges pharmacists to practice due diligence, vetting ingredients and confirming that there has been third-party testing for impurities, heavy metals, and other substances.

CBD products are often erroneously advertised as devoid of drug interactions. Evidence shows that CBD is well tolerated sans psychotic effects, provided doses do not exceed 600 mg. However, CBD potently inhibits CYP3A4 and CYP2D6 enzymes, which could cause higher-than-normal increases in serum concentrations of calcium channel blockers, benzodiazepines, antihistamines, antiretrovirals, statins, cyclosporine, and other drugs cleared through these enzymes.

For more information and to stay up-to-date on issues in dietary supplements and integrative health, visit 

Patients seeking vitamin or herbal supplements for health and wellness often believe that these are safer than conventional OTC and prescription pharmaceutical products; however, so-called natural remedies come with their own set of health risks.

Integrative Medicine Presents Opportunities, Poses Challenges

In the wake of the novel coronavirus 2019 (COVID-19) pandemic, pharmacists face an ongoing challenge with helping patients optimally manage chronic conditions.

In HIV care, for example, pharmacists play a key role in monitoring treatments, counseling patients, and assisting with adherence challenges, all of which current social distancing measures can make more difficult. Furthermore, the potential effects of the COVID-19 virus on patients with HIV remain uncertain, even as reports indicate that other chronic conditions such as diabetes and hypertension may put affected individuals at higher risk.

“So far, there is no major report to suggest that HIV patients are more or less susceptible to COVID-19 than individuals who do not have HIV or are otherwise healthy,” Rodney Ho, PhD, professor of pharmaceutics at the University of Washington School of Pharmacy in Seattle, told 

According to a statement on Aidsinfo, a US Department of Health & Human Services website, the “limited data currently available do not indicate that the disease course of COVID-19 in persons with HIV differs from that of persons without HIV.” However, the website subsequently states that the use of effective antiretroviral therapy (ART) in the HIV population might be responsible for the current trend. Before the introduction of ART, a CD4 cell count below 200/mm3 was considered a risk factor for complications resulting from other respiratory infections. At press time, the website stated that whether HIV increases COVID-19 risk is still unknown. Until experts know for sure, the scientific consensus is that proactive measures to limit risk and exposure to COVID-19 should bear little difference to the measures taken by individuals who are generally healthy.

Health care systems have taken precautions to mitigate exposure and risk for patients with HIV. Perhaps the most significant change involves encouraging patients to stay home unless clinicians feel an office visit is medically necessary.

Clinicians are also taking proactive measures to prevent drug shortages and limit onsite visits. As a result, mail order use has surged. “We reach out to patients via phone around 5 to 10 days ahead of their next refill, so we can mail out their prescriptions to enhance adherence,” said a Houston, Texas–area HIV pharmacist who practices at an outpatient pharmacy located in a health center and wants to remain anonymous. “Sometimes we match the date with the patient’s next clinic visit and have their medications ready, making it easier for them to have access during the pandemic.”

In addition to enacting medication synchronization, the pharmacist’s organization now issues emergency fills and early refills to reduce or eliminate multiple trips to the pharmacy. Patients who pick up their prescriptions must maintain a 6-foot distance from other patients. The clinic also requires these patients to fill out a COVID-19 screening form that helps pharmacists determine who needs additional assistance or medical attention.

Physical distandistancing in the HIV community has driven a massive uptick in telemedicine services. Many patient interactions, such as follow-up visits and education, now occur remotely. Although the industry trend indicates that most services for this patient population have gone remote, exceptions may apply with at-risk populations.

For example, providers at ChristianaCare’s William J. Holloway, MD, Community Program in Wilmington, Delaware, might require a site visit for patients who are older than 60 years or have certain disease states, such as lung disease and hypertension. “We are using virtual and telephonic visits, as well as preset algorithms for COVID,” said Kelly Cantwell-McNelis, PharmD, AAHIVP, a clinical pharmacy specialist with the community program.

In the outpatient pharmacy based in Houston, Texas, pharmacists make adherence calls to patients to monitor refills while screening them for signs and symptoms of the virus. “Since HIV patients are immunocompromised, we ask them if they are experiencing dry cough, fever, or chills currently, and document them in our pharmacy software,” the HIV pharmacist at the clinic said.

Phone calls and tracking prove critical because the clinic has a high number of patients with CD4 counts falling below 200 mm3, a sign of full-blown AIDS. These patients receive regular phone calls to monitor and address adherence, as well as to screen patients for opportunistic infections. Because of the pandemic, patients are now given the COVID-19 screening questionnaire over the phone.

Although telemedicine interventions have made operations more efficient, there have been hurdles. For instance, helping patients understand why they should call the pharmacy before making a trip has become a teaching opportunity that requires vigilance. “It took us a couple of weeks to get patients to understand that they should call us first and let us triage their symptoms,”said Cantwell-McNelis.

On the virtual front, Dan Scales, PharmD, AAHIVP, director of collaborative care pharmacy at Vivient Health and owner and founder of Scales Pharmacy in Denver, Colorado, and his colleagues have worked diligently to get up to speed on a new technological platform. He said that he thinks the process has gone generally well but recognizes that success also depends on the patient’s resources. Scales noted major obstacles with a patient living in a rural area. “We have to use video relay because the patient’s internet connection is not stable enough to hold a conversation in real time,” Scales said. Because the patient is deaf, interaction also requires a sign language interpreter.

Historically, the health care industry has wrestled with telemedicine navigating the nebulous web of integration and reimbursement. If there is any benefit from the pandemic, it is the swift action to establish and bill for telemedicine services, according to Cantwell-McNelis. She cited a recent 

 article highlighting the near-overnight transition. “The speed of the transition has been dizzying. Changes that would typically encompass months of planning, pilot testing, and education have been compressed into days,” the authors wrote.

With no viable cure or treatment for COVID-19 yet, investigators are exploring the potential benefit of antiviral protease inhibitors (PIs) routinely used in HIV medicine. The findings’ effects on the HIV population continue to unfold with emerging data and research.

At press time, 15 studies exploring the effects of PIs on COVID-19 were found on ClinicalTrials.gov. Results from a randomized, controlled, open-label clinical trial on lopinavir-ritonavir (Kaletra) following 199 patients in China showed that the drug did not speed recovery or reduce the viral load in patients with COVID-19.

“Until we know more about how PIs affect COVID-19, people with HIV should not switch their HIV medicine in attempt to prevent or treat COVID- 19,” Scales warned.

Sources predict lasting changes in the post-COVID era of pharmacy. Scales and Cantwell-McNelis foresee telemedicine becoming a mainstay of treatment. Ho believes that the dynamics of the virus will further elevate the demand and profile of pharmacists’ contributions to the health care system by serving as a resource to the physician.

“Many physicians are emergency room doctors or heart specialists who are not trained in infectious diseases or to think about DDIs [drug-drug interactions] and how to monitor for heart conditions,” Ho said. “The pharmacist’s role is to serve as an expert when the physicians are caring for patients by looking for data to provide the best evidence available and being able to develop appropriate time-sensitive information.”

Virtual care takes center stage amid the pandemic.

Pharmacists Fight HIV

In the ever-changing world of diabetes devices, pharmacists need to stay on top of developments so that they can answer patients’ questions about what is available.

Continuous glucose monitors (CGMs) are used increasingly to help patients with diabetes monitor and treat blood sugar levels, said Panteha Kelly, RPh, BCACP, APh, CDE, a clinical pharmacist specialist and clinic coordinator at the University of California, San Diego, Health Diabetes Self-Management Clinic in La Jolla, California.

Continuous scanning, or real-time, CGMs provide a constant reading of interstitial glucose to a receiver or smart device, and alarms alert the wearer when glucose is approaching patient thresholds for hyper- or hypoglycemia. In contrast, intermittently scanning, or flash, CGMs require the user to swipe the transmitter over the sensor to display data from the previous 15 minutes, including trend arrows showing whether blood sugar is rising or dropping and how quickly; they do not have alarms or alerts.

The most popular CGM on the market is the Dexcom G6 system. Unlike earlier Dexcom models and the other real-time CGMs, Guardian Connect and Eversense, Dexcom G6 does not require finger sticks for calibration. Eversense requires implant and removal every 3 months in office by a provider.

Jennifer Trujillo, PharmD, FCCP, BCPS, CDE, BCADM, believes that once it has been on the market for a while longer and gets approval for longer wear (6 or 12 months), it will likely be used more. Trujillo is an ambulatory care pharmacist and certified diabetes care and education specialist at the University of Colorado Anschutz Medical Campus Center for Adult Diabetes Care and Research in Aurora.

Freestyle Libre is the only flash CGM; it costs less than the Dexcom G6 and is easier to use, Trujillo said. Kelly cautioned that it must be scanned at least once every 8 hours to save the data for review later.

Real-time CGMs are usually preferred for patients with type 1 diabetes, who need close monitoring of their blood glucose and alerts, whereas flash CGMs are appropriate for patients with type 2 diabetes. The alarms on a real-time CGM can be lifesaving by, for example, alerting patients with hypoglycemic unawareness when their blood sugar is dropping, so they know not to drive, Kelly said.

“Real-time CGMs also allow data sharing, so it’s a great option for kids so that their parents can have the CGM data on their phones, as well,” Trujillo said.

About half of Trujillo’s patients with type 1 diabetes use insulin pumps. “The evidence at this point indicates that patients can achieve good glucose control in a variety of different ways, either through injection therapy or through insulin pump therapy, so I think it requires a thoughtful conversation between the patient and the provider,” she said.

Hybrid closed-loop systems combine the functionality of a CGM with a pump to automate insulin delivery based on real time glucose values. The first hybrid closed-loop system, Medtronic’s MiniMed 670G, was approved in 2016. This CGM communicates with an insulin pump designed to decrease or stop insulin when glucose is low and increase insulin delivery when glucose is high, without input from the user.

Tandem’s t:slim X2 Insulin Pump with Basal-IQ technology was approved in 2018 as an insulin pump and CGM: The pump suspends insulin delivery if the CGM detects glucose falling below a predefined threshold.

Tandem’s next advance, approved in December 2019, is Control-IQ technology, which automatically increases, decreases, or suspends delivery of basal insulin based on insulin delivery history, CGM data, and predicted glucose values. Control-IQ uses the Dexcom G6 CGM with the t:slim pump.

For patients who have traditional insulin pumps, Trujillo said, providers track glucose trends over 3 or 6 months and work with the patients to adjust basal insulin rates for different times of day. “[This is as] opposed to the hybrid closed-loop insulin pumps, where the basal rates are constantly changing based on the glucose readings from the CGM,” she explained. “There is encouraging evidence that the hybrid closed-loop systems can improve glucose variability, particularly overnight.”

Patients are slowly transitioning to newer models but still represent a small percentage of patients with type 1 diabetes, Trujillo said.

Patients should be carefully selected, according to Kelly. “I can’t give a closed-loop system to just anybody at this time, because if it malfunctions [or] if someone has a low health literacy, it can be dangerous.”

Medicare typically covers CGMs for patients with diabetes who test their blood sugar at least 4 times a day and take multiple daily doses of insulin, Trujillo said. She believes that almost all patients with type 2 diabetes can benefit from a flash CGM. “Knowledge is very powerful,” she said, “and when you’re able to see your glucose values all day long without sticking your finger, that information can create important behavioral changes and can create more understanding of how medications are working and how different behaviors are influencing glucose.”

Patients can observe how stress, lack of sleep, and lack of exercise negatively affect their blood glucose control, whereas exercise and healthy eating improve glucose control, she said: “Seeing that over time can certainly improve glucose management overall.”

The 2 most popular CGMs can be dispensed in pharmacies, which places pharmacists in an ideal position to counsel patients about these devices, especially because most patients with type 2 diabetes are managed by primary care providers who may be less familiar with diabetes technology advances, Trujillo said.

Kelly emphasized that patients need to understand that when starting to use a CGM, they cannot draw conclusions regarding diabetes management until they have collected 10 to 14 days of data. To capture nighttime data, she noted that patients starting to use the Freestyle Libre should scan their device both right before going to bed at night and upon waking up in the morning.

Trujillo encourages pharmacists to learn more about CGMs by taking continuing education courses and watching tutorials on the manufacturers’ websites. “It’s challenging to keep up on the latest and greatest but certainly important for a frontline health care provider like a pharmacist to do so,” she said.

Pharmacists must be tuned in to the latest technology for patients who monitor blood glucose.

Get Educated on Diabetes Devices 

Vaccines are crucial to protect public health globally, and pharmacists can play an important role in educating
	patients on the importance of immunizations. The World Health Organization named vaccine hesitancy as one of the 10 global threats of 2019. The measles outbreak was largely fueled by the antivaccination movement, and between January 1, 2019, and December 31, 2019, there were 1282 confirmed measles cases across 31 states. This was the greatest number of cases reported in the United States since 1992, a majority of which occurred in patients who were not vaccinated against measles. The cases included 128 patients requiring hospitalization, with 61 patients experiencing complications such as pneumonia and encephalitis. As of May 7, 2020, there have been 12 confirmed measles cases in 7 jurisdictions. Adults and children should be encouraged to stay up-to-date on their immunizations to combat vaccine-preventable diseases. Children can be protected against 14 diseases by 2 years of age when they are up-to-date with their vaccines.

Measles and Combating the Anti-Vaccination Movement 

Pharmacists should educate families and debunk the myth that the measles, mumps, and rubella (MMR) vaccine causes autism. The CDC recommends that all children receive 2 doses of the MMR vaccine: the first at 12 to 15 months of age and the second at 4 to 6 years of age. The Wakefield study published in 

 in 1998 ignited fear among the public that the MMR vaccine caused autism, but it was fraudulent. The study was retracted, and author Andrew Wakefield lost his medical license. However, those opposed to vaccination continue to cite the false claim that links the MMR vaccine with autism, which has contributed to a decline in vaccination and increased the spread of measles globally. One recent large-scale study involving 657,461 Danish children over a 10-year period demonstrated that there is no link between the MMR vaccine and autism.

Pharmacists should educate families about the negative health consequences of vaccine refusal for children and adults, especially regarding the MMR vaccine. Measles can result in serious complications: pneumonia, encephalitis, permanent hearing loss, hospitalization, and death. Refusing the vaccine also puts those who are too young to receive it or immunocompromised at risk. Many social media platforms, such as Facebook, Twitter, Pinterest, and YouTube, have taken steps to counter vaccine misinformation, but inaccurate information is still spreading globally. One study based on surveys of almost 2500 US adults found that up to 20% of participants were somewhat misinformed about vaccines. Survey participants who reported increased exposure to information about measles and the MMR vaccine on social media were more likely to grow more misinformed about immunizations. However, those who reported increased exposure to these health topics in traditional media were less likely to support antivaccination claims. Some noteworthy study findings include the fact that 18% of participants mistakenly believe it is very or somewhat accurate that vaccines cause autism. Also, 20% incorrectly report that it makes no difference if parents choose to delay or spread out childhood vaccines instead of adhering to the CDC-recommended immunization schedule.

According to a study by Health Testing Centers, between 2009 and 2018, 27 US states experienced a decline in the percentage of vaccinated kindergarten-age children. Data from the CDC were used to analyze vaccine rates for kindergartners for the most common immunizations, including MMR; diphtheria, tetanus, and pertussis (DTaP); polio; hepatitis B; and varicella. The results found that MMR vaccination rates fell below the 95% target aimed at providing the best protection against measles in 26 states.

The benefits usually outweigh any risks when it comes to vaccines, said Mary Malek, PharmD, AAHIVP, a pharmacist specializing in HIV who practices in New York. “As pharmacists, we must continue to recommend vaccinations to all our patients,”Malek said.“In order to combat the antivaccination movement, we have to use logic and numbers that tell the story.”

Measles was declared eliminated in the United States in 2000, but in the past 5 years especially, there has been an increase in cases. “Reassuring parents is needed, and using data to support that, I believe, is key. If we do not learn from our past, we will never be able to have a better future,” Malek said. Pharmacists can use social media platforms to educate the public and champion vaccines. Community outreach programs and health fairs are also great ways to spread the word about being up-to-date on vaccines. Additionally, pharmacists can advocate for stricter state vaccine laws regarding religious or philosophical exemptions.

During the 2019-2020 influenza season, 174 influenza-associated pediatric deaths were reported to the CDC as of May 9, 2020. This past season, influenza-associated hospitalizations in the United States were higher overall than in most recent seasons, and rates for children aged 0 to 4 years and adults 18 to 49 years were the highest the CDC has on record for these age groups, ex- ceeding the rates reported during the 2009 H1N1 pandemic. The CDC’s interim report revealed that the influenza vaccine was 45% effective overall against any influenza virus. Additionally, the vaccine offered a substantial protection of 55% efficacy against the illness among children and adolescents aged 6 months to 17 years. These results are consistent with those from previous influenza seasons, which ranged from 40% to 60%. Children should receive the vaccine as soon as it becomes available, especially those receiving it for the first time as they need 2 doses. The American Academy of Pediatrics has no preference for using flu shots over nasal sprays for the 2020-2021 season. The CDC’s Advisory Committee on Immunization Practices plans to meet this summer but is not expected to make major changes for the upcoming influenza season.

Patients are sometimes hesitant to get an influenza shot because the efficacy can vary each season, so it is important for pharmacists to tell patients that an annual vaccine for everyone 6 months and older is the best way to protect against the illness. Evidence demonstrates that the vaccine protects against influenza-related complications such as hospitalization and death. One study examined the impact of pharmacy-based immunization services on the likelihood of patients receiving the adult influenza and pneumococcal vaccines. The study found that patients were likely to be vaccinated against influenza and pneumonia after receiving the im- munization services.10 As some of the most accessible health care professionals, pharmacists can play an important role in increasing influenza immunization rates.

Pregnant women are at higher risk of influenza-related complications, so it is especially important for this pop- ulation to be vaccinated. Influenza vaccination during pregnancy also provides passive immunity to the baby during the first few months of life. One CDC report revealed that only 53.7% of pregnant women received the influenza vaccine; therefore, pharmacists can play a vital role in educating pregnant patients about the importance of the vaccine.

Pharmacists can stay up-to-date with the latest vaccine information through the CDC website. The Immunization Action Coalition also includes information on all immunizations as well as frequently asked questions. Further, the CDC has a free Vaccine Schedules app that includes all recommended immunizations for children and adults. The agency also created a free app called the PneumoRecs VaxAdvisor to help determine which pneumococcal vaccines patients need based on their age and medical history.

“As pharmacists, we must continue to recommend vaccinations to all our patients.”

Keep Current on Vaccines to Reassure Hesitant Patients

Over 80 autoimmune diseases affect an estimated 14.7 million to 23.5 million people in the United States.

The mainstays of therapy consist of nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, disease-modifying antirheumatic drugs (DMARDs), and anti–tumor necrosis factor (TNF)–Î± biologics, but various products over the counter also help relieve symptoms. Pharmacists can help patients select the appropriate OTC medications in light of special considerations related to their conditions.

For rheumatoid arthritis (RA) and other autoimmune diseases, NSAIDs can be a good starting point for relieving pain and inflammation, said Wendy Ramey, BSPharm,RPh,CSP,clinicalpharmacist with a specialty in inflammatory conditions at University of Kentucky’s specialty pharmacy and infusion services in Lexington. For some conditions, such as ankylosing spondylitis, most insurance companies require that patients try OTC or prescription NSAIDs before being approved to move on to biologics, she said.

Ramey recommends that patients limit OTC NSAID use to short periods. “If they need to go beyond 2 or 3 weeks of everyday use, then they’re going to need to talk to us about some other kind of treatment to take care of their pain,” she said.

Community pharmacists who notice patients with autoimmune diseases consistently buying these OTC products should initiate a discussion regarding use, said Jessica Farrell, PharmD, clinical pharmacist at the Center for Rheumatology at the Albany College of Pharmacy and Health Sciences in New York. “If [patients are] using lots of NSAIDs consistently with a DMARD-methotrexate, hydroxychloroquine, sulfasalazine-or a TNF inhibitor...then maybe that DMARD or biologic is not adequate,” Farrell said. Patients should be advised to speak with their provider about trying a different therapy. Patients also should take a histamine-2 receptor blocker or proton pump inhibitor (PPI) because of gastrointestinal toxicities related to NSAIDs, she advised.

Pharmacists can recommend other OTC products to manage symptoms. For patients with inflammatory arthritis, Farrell encourages use of OTC topical pain-relief prod- ucts such as lidocaine patches and diclofenac gel. “These are great options for patients who have more mild disease or in smaller joints or for small flares that don’t require systemic therapy,” she said.

Pharmacists also can guide patients toward OTC products to treat the dry mouth and eyes associated with SjÃ¶gren syndrome. “Many of our patients [with] other au- toimmune diseases have overlap SjÃ¶gren syndrome,” Farrell reported. Various products treat dry mouth, including mouthwashes, gums, and toothpastes, and it often takes trial and error to find what works best for each patient, she said. Patients with SjÃ¶gren may need help finding the right eye drops, whether they need a preservative-free product or one for sensitive eyes. Gel-like drops can be particularly helpful for patients with severe nighttime dryness that interferes with sleep, Farrell said.

Mild injection site reactions in patients on injectable therapies can be treated with OTC topical steroids or antihistamines, according to Farrell.

For patients who complain of insomnia, which can be caused by an autoimmune disease or its treatment, Ramey recommends melatonin products rather than antihistamines, which can have other unwanted effects.

Various nutritional supplements also play a role in managing autoimmune diseases. Folic acid supplementation is crucial to reduce the gastrointestinal and liver toxicities of methotrexate therapy in patients with RA. Although most patients take prescription folic acid, Farrell said, some use the OTC version. Recommendations on amounts vary, but common regimens consist of 1 mg daily or 5 mg once weekly.

Some data suggest that cherries and cherry extract products have antioxidant properties and reduce inflammation in patients with gout. Farrell commonly adds those products as an adjunct for patients taking uric acid–lowering therapies, such as allopurinol and febuxostat, who need additional urate-lowering therapy but for whom adverse effects preclude increased doses.

Patients taking NSAIDs should be taught to carefully check labels of OTC combination products to prevent overdosing on NSAIDs, Farrell said. “That’s one of the things that I teach my patients a lot about: reading labels and how to recognize if they’re taking products that have multiple drugs in them, so they’re not double dosing on ibuprofen or taking ibuprofen and naproxen at the same time,” she said.

Patients with SjÃ¶gren should be ad- vised to avoid OTC products containing decongestants and first-generation antihistamines, which can exacerbate dryness, Farrell said: “Sometimes patients take Tylenol PM; they don’t realize that it has diphenhydramine, so it’s drying them out even more.” For relief from seasonal allergy symptoms, second-generation antihistamines are preferable, she said.

Patients with RA who are looking for immune-boosting supplements also need to scrutinize labels. Ingredients such as zinc and vitamin C are fine to take, Farrell said, but pharmacists should warn patients to steer clear of products that contain astragalus, an herb that increases TNF-É.

An important drug interaction in this population occurs between immuno-suppressant mycophenolate mofetil and PPIs, Farrell noted. PPIs can reduce absorption of mycophenolate mofetil, which requires an acidic environment for optimal absorption, so patients should take mycophenolate mofetil at least 90 minutes before the PPI. Pharmacists are in an ideal position to alert patients about this interaction, she said, because physicians might not be aware that their patients are taking OTC PPIs.

To avoid toxicity, acetaminophen use should be limited to 2 g per day in patients taking drugs that are metabolized by the liver, Ramey said. Farrell noted that in patients taking hydroxy- chloroquine, any OTC product potentially associated with increased risk of QTc prolongation, such as pseudo-ephedrine, could be problematic.

“For the most part, we [in the field of rheumatology] are very lucky to have drugs that don’t cause us very many [drug interaction] problems,” Ramey said.

Pharmacy software might flag an interaction between methotrexate and NSAIDs, but that is not clinically relevant in this patient population, Farrell said. NSAIDS can prevent excretion of methotrexate, which is used in high doses in oncology, and result in toxicity, but that is not an issue at the doses used in autoimmune diseases, she said.

Because so many patients with autoimmune disease take immunosuppressants, pharmacists counseling them should be on the lookout for infections.

“If a patient with an autoimmune disease is coming in looking for something to treat a possible infection, like [OTC] bactericidal ointments or creams, that would be the first clue that something needs to be addressed with their doctor,” Ramey said. “Because most of our medications increase the risk of infection, we always want to know if a patient has a cut or a bug bite that is starting to look infected; that is our biggest concern.”

Patients on immunosuppressants who want to buy OTC cough or cold products should be reminded that their current treatments prevent them from fighting infections. “If they’re on methotrexate, sometimes, if it’s a very mild infection, we might not have to hold it, but if they’re on biologics, they definitely should hold during an infection.”

The right products can help manage symptoms of autoimmune diseases.

Offer Patients OTC Pointers

When it comes to cybersecurity threats related to the Health Insurance Portability and Accountability Act (HIPAA), pharmacists are in a unique and rather unenviable position.

Joey Mattingly, PharmD, PhD, MBA, an associate professor and vice chair of academic affairs of Pharmaceutical Health Services Research at the University of Maryland School of Pharmacy in Baltimore, teaches a pharmacy management course that examines practical implications of HIPAA. Like all businesses, pharmacies are susceptible to cyberattacks, he said, so it is important to have an information security plan that covers everything from training to what to do if a breach occurs.

“Many large chain pharmacies have well-established policies and procedures, but a start-up pharmacy or smaller organization may not have as large of an infrastructure in place,” Mattingly told Drug Topics®.

Recent data breaches with large companies and potential interference in major political elections have heightened attention to cybersecurity concerns, and it is paramount that pharmacists understand their existing company policies, Mattingly said. Pharmacists starting their own businesses should consider hiring information technology experts to establish detailed standard operation procedures specific to security.

“Err on the side of caution. One large data breach could [affect all] your patients, your employees, and yourself. The fallout from a data breach could be devastating and potentially ruin your business, particularly since it involves our patients’ personal health information,” he said.

Investing in proper training is key. Mattingly advocates taking the time to teach, review best practices, and make sure all employees practice what they learned. “Test your processes and systems for security gaps,” he said. “Many retail stores use secret shoppers to test customer service, [and] a pharmacy can use this technique to see if any of your employees would fall for a basic hacking ploy [such as a phishing email].” Mattingly advises focusing on best practices rather than failures: “You should provide incentives for your pharmacists and technicians who do things right.”

Pharmacists now have more tools and technologies to protect their data, but cyber criminals have also developed new strategies, and the risk continues
	to evolve, according to Mattingly. Protecting against a cyberattack should be viewed as a business expense or op- erating cost, he noted. “Pharmacies are already pressured with decreasing margins on pharmacy sales, so it is important that pharmacists advocate for either increased revenues for pharmacies or other financial support [such as low-interest loans and tax incentives] for technology and training investments,” he said.

Neil Edillo, PharmD, assistant direc- tor of pharmacy services and information management and medication safety at Oregon Health & Science University (OHSU) in Portland, said that as far as he knows, no cyberattacks have targeted only the pharmacy community.

“Pharmacists can fall victim to the same schemes that are applied broadly to everyone. There are quite a few ways that hackers can attempt to gain unlawful access to our systems, and as a health system, we have instituted a number of interventions at the individual level to help safeguard login information,”Edillo said. All systems should require strong passwords with special characters, and all employees should be required to change passwords every 90 days, he said, underscoring the importance of 2-factor authentication.

“The primary threat to obtain user log-in credentials is phishing. As great as our email servers are, some of these email attempts are able to find their way through to our end users. Our health system has provided education about what phishing attempts look like and what to do with them,”Edillo said. OHSU has instituted test programs in which they internally generate a phishinglike email that is distributed to all users across the university and health system from an outside mail server. “If the user clicks on the links contained in the email, they are immediately provided instruction on phishing attempts and to maintain their vigilance against cybersecurity threats,” Edillo told 

Pharmacists interested in protecting themselves and their customers from cyberattacks need to invest in vendors that handle their data, according to investigators at American University in Washington, DC. They conducted a study and found that a data breach due to a third-party supplier was more likely to lead to an underinvestment in cybersecurity measures. The study authors wrote that all companies need to look at every entity that handles their data-just 1 weak link and the system is compromised. Study coauthor Jay Simon, PhD, an associate professor of information technology and analytics at American University’s Kogod School of Business, said there is a huge range of cybersecurity threats, depending on the systems, data involved, and the attackers’ goals. “A computer needs to have adequate security settings and software, but the user also needs to understand how to avoid installing malware or falling for phishing scams. Pharmacists face the added legal and ethical ramifications of having sensitive personal data compromised, which makes all these measures even more crucial,” Simon told 

A few years ago, Merck was hit with a serious ransomware attack, which is a common issue for health care providers, according to Simon. Last June, 5 US health care organizations reported ransomware attacks, with some having to pay to regain access to files.

“Keep your security software up- to-date, and understand the common techniques that attackers use. Good password management and not clicking on anything suspicious goes a long way. Be restrictive about who’s allowed access to your computers and network, both physically and electronically,” he said.
	Lisa Schwartz, PharmD, senior director of professional affairs at the National Community Pharmacists Association in Alexandria, Virginia, said that like any business, pharmacies face the threat of having digital records hacked. However, these vulnerable data include not just personnel and financial records of the business, but also patient health information, which opens pharmacies up to scrutiny by the US Department of Health & Human Services Office for Civil Rights, which enforces HIPAA.

“It makes sense for pharmacists and pharmacy owners to use many of the tools that are available to HIPAA-covered entities and organizations trying to improve cybersecurity. These include virtual private networks, firewalls, and antivirus software,” Schwartz said. “[Although] those tools help protect the pharmacy management system from cyberattacks, inappropriate access by employees of the pharmacy is another concern.” Pharmacy owners should seek advice from software vendors about the access controls and the best method of monitoring, according to Schwartz. “For example, the pharmacy’s privacy officer could have an alert in place anytime a high-profile patient’s record is accessed to prevent unauthorized use or disclosure,” Schwartz said.

Today’s tactics are more subtle than those of the past, Schwartz said. Cyber criminals often try to collect bits of personal data to trick individuals into replying to an email or clicking a link they would normally discard if it snuck though a spam filter. “Pharmacists and pharmacy staff can do their part to minimize cybersecurity threats by only using pharmacy computers to access trusted websites and to be careful about opening attachments or clicking links in email,” Schwartz said. “For example, if a technician receives an email that appears to be from a familiar vendor but contains an unexpected invoice, call the sender and ask if it is legitimate.” Fred H. Cate, JD, vice president for research and a professor of law at Indiana University, said pharmacists are seeing more desperate requests for help to provide a drug without a prescription or help a patient with shipping or supply chain delays related to the pandemic. “Most of these requests are almost certainly legitimate, but that is just how a criminal would approach a pharmacy, as well, whether in a classic fraud attack or in an effort to find access information [or] an unlocked machine or other ways to infiltrate the system,”Catesaid. In recent years, he said, many attacks originated from people sitting in cars in parking lots using wireless access through the payment or other systems. Cate added that because of the pandemic, pharmacists need to be vigilant. “These types of attacks are more likely to succeed and less likely to be noticed when there are other stresses on the system,” Cate said.

“Err on the side of caution. One large data breach could [affect all] your patients, your employees, and yourself.”

Drug Topics June 2020